Comments
Loading...

10x Genomics Analyst Ratings

TXGNASDAQ
Logo brought to you by Benzinga Data
$9.34
0.485.36%
At close: -
$9.34
0.000.00%
After Hours: 4:00 PM EDT
Consensus Rating1
Neutral
Highest Price Target1
$60.00
Lowest Price Target1
$6.50
Consensus Price Target1
$23.79

10x Genomics Analyst Ratings and Price Targets | NASDAQ:TXG | Benzinga

10x Genomics Inc has a consensus price target of $23.79 based on the ratings of 20 analysts. The high is $60 issued by Goldman Sachs on July 14, 2022. The low is $6.5 issued by Goldman Sachs on May 12, 2025. The 3 most-recent analyst ratings were released by Morgan Stanley, Stephens & Co., and UBS on May 19, 2025, May 15, 2025, and May 13, 2025, respectively. With an average price target of $14.67 between Morgan Stanley, Stephens & Co., and UBS, there's an implied 57.11% upside for 10x Genomics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jan
6
3
Feb
1
Mar
1
Apr
3
2
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Morgan Stanley
Stephens & Co.
UBS
Goldman Sachs
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for 10x Genomics

Buy NowGet Alert
05/19/2025Buy Now92.82%Morgan Stanley
Tejas Savant50%
$26 → $18MaintainsOverweightGet Alert
05/15/2025Buy Now49.97%Stephens & Co.
Mason Carrico39%
$14 → $14ReiteratesOverweight → OverweightGet Alert
05/13/2025Buy Now28.55%UBS
Dan Leonard54%
$14 → $12MaintainsNeutralGet Alert
05/12/2025Buy Now-30.37%Goldman Sachs
Matthew Sykes62%
$7.5 → $6.5MaintainsSellGet Alert
05/12/2025Buy Now60.69%Canaccord Genuity
Kyle Mikson36%
$18 → $15MaintainsBuyGet Alert
05/09/2025Buy Now-3.59%JP Morgan
Rachel Vatnsdal66%
$12 → $9MaintainsNeutralGet Alert
04/10/2025Buy Now28.55%Barclays
Luke Sergott50%
$15 → $12MaintainsOverweightGet Alert
03/04/2025Buy Now60.69%Citigroup
Patrick Donnelly80%
$20 → $15MaintainsBuyGet Alert
02/14/2025Buy Now178.52%Morgan Stanley
Tejas Savant50%
$28 → $26MaintainsOverweightGet Alert
02/14/2025Buy Now60.69%Barclays
Luke Sergott50%
$18 → $15MaintainsOverweightGet Alert
02/13/2025Buy Now92.82%Canaccord Genuity
Kyle Mikson36%
$20 → $18MaintainsBuyGet Alert
02/13/2025Buy Now114.25%Citigroup
Patrick Donnelly80%
$23 → $20MaintainsBuyGet Alert
02/13/2025Buy Now28.55%JP Morgan
Rachel Vatnsdal66%
$14 → $12MaintainsNeutralGet Alert
02/13/2025Buy Now49.97%UBS
Dan Leonard54%
$20 → $14MaintainsNeutralGet Alert
02/13/2025Buy Now92.82%Stifel
Daniel Arias78%
$21 → $18MaintainsBuyGet Alert
02/13/2025Buy Now28.55%Leerink Partners
Mike Kratky65%
$25 → $12DowngradeOutperform → Market PerformGet Alert
02/10/2025Buy Now92.82%Barclays
Luke Sergott50%
$19 → $18MaintainsOverweightGet Alert
01/13/2025Buy Now199.95%Morgan Stanley
Tejas Savant50%
$30 → $28MaintainsOverweightGet Alert
11/01/2024Buy Now103.54%Barclays
Luke Sergott50%
$21 → $19MaintainsOverweightGet Alert
10/30/2024Buy Now146.38%Citigroup
Patrick Donnelly80%
$35 → $23MaintainsBuyGet Alert
10/30/2024Buy Now49.97%Goldman Sachs
Matthew Sykes62%
$16 → $14MaintainsSellGet Alert
10/30/2024Buy Now49.97%JP Morgan
Rachel Vatnsdal66%
$20 → $14MaintainsNeutralGet Alert
10/30/2024Buy Now114.25%UBS
Dan Leonard54%
$25 → $20MaintainsNeutralGet Alert
10/15/2024Buy Now124.96%Barclays
Luke Sergott50%
$24 → $21MaintainsOverweightGet Alert
10/10/2024Buy Now221.37%Stephens & Co.
Mason Carrico39%
$30 → $30ReiteratesOverweight → OverweightGet Alert
10/10/2024Buy Now114.25%Canaccord Genuity
Kyle Mikson36%
$32 → $20MaintainsBuyGet Alert
09/04/2024Buy Now221.37%Stephens & Co.
Mason Carrico39%
$30 → $30ReiteratesOverweight → OverweightGet Alert
09/03/2024Buy Now274.93%Leerink Partners
Mike Kratky65%
→ $35Initiates → OutperformGet Alert
08/13/2024Buy Now167.81%UBS
Dan Leonard54%
$30 → $25MaintainsNeutralGet Alert
08/13/2024Buy Now392.77%Morgan Stanley
Tejas Savant50%
$50 → $46MaintainsOverweightGet Alert
07/23/2024Buy Now242.8%Canaccord Genuity
Kyle Mikson36%
$50 → $32MaintainsBuyGet Alert
07/22/2024Buy Now157.1%Jefferies
Tycho Peterson81%
$24 → $24UpgradeHold → BuyGet Alert
07/18/2024Buy Now167.81%B of A Securities
Derik De Bruin84%
$36 → $25MaintainsNeutralGet Alert
07/18/2024Buy Now114.25%JP Morgan
Rachel Vatnsdal66%
$40 → $20DowngradeOverweight → NeutralGet Alert
07/16/2024Buy Now167.81%Stifel
Daniel Arias78%
$53 → $25MaintainsBuyGet Alert
07/10/2024Buy Now167.81%Deutsche Bank
Justin Bowers46%
$55 → $25DowngradeBuy → HoldGet Alert
07/09/2024Buy Now71.4%Goldman Sachs
Matthew Sykes62%
$26 → $16MaintainsSellGet Alert
06/28/2024Buy Now157.1%Barclays
Luke Sergott50%
$36 → $24MaintainsOverweightGet Alert
06/27/2024Buy NowWolfe Research
Doug Schenkel71%
DowngradeOutperform → Peer PerformGet Alert
06/26/2024Buy NowGuggenheim
Subbu Nambi41%
DowngradeBuy → NeutralGet Alert
06/25/2024Buy NowGuggenheim
Subbu Nambi41%
DowngradeBuy → NeutralGet Alert
06/03/2024Buy Now157.1%Jefferies
Tycho Peterson81%
→ $24Initiates → HoldGet Alert
05/01/2024Buy Now221.37%UBS
Dan Leonard54%
$52 → $30MaintainsNeutralGet Alert
05/01/2024Buy Now285.65%B of A Securities
Derik De Bruin84%
$45 → $36MaintainsNeutralGet Alert
05/01/2024Buy Now178.52%Goldman Sachs
Matthew Sykes62%
$30 → $26MaintainsSellGet Alert
05/01/2024Buy Now242.8%TD Cowen
Dan Brennan62%
$57 → $32DowngradeBuy → HoldGet Alert
05/01/2024Buy Now467.76%Stifel
Daniel Arias78%
$63 → $53MaintainsBuyGet Alert
04/29/2024Buy Now435.62%Canaccord Genuity
Kyle Mikson36%
$65 → $50MaintainsBuyGet Alert
04/18/2024Buy Now489.18%Deutsche Bank
Justin Bowers46%
$60 → $55MaintainsBuyGet Alert
04/10/2024Buy Now382.06%Barclays
Luke Sergott50%
$55 → $45MaintainsOverweightGet Alert
02/16/2024Buy Now574.88%Stifel
Daniel Arias78%
$68 → $63MaintainsBuyGet Alert
01/25/2024Buy Now489.18%Barclays
Luke Sergott50%
$45 → $55MaintainsOverweightGet Alert
12/14/2023Buy Now542.74%Guggenheim
Subbu Nambi41%
→ $60Initiates → BuyGet Alert
12/13/2023Buy NowWolfe Research
Doug Schenkel71%
Initiates → OutperformGet Alert
12/12/2023Buy Now478.47%B of A Securities
Derik De Bruin84%
$36 → $54UpgradeUnderperform → NeutralGet Alert
09/29/2023Buy Now403.48%Barclays
Luke Sergott50%
$66 → $47MaintainsOverweightGet Alert
09/19/2023Buy Now649.87%Canaccord Genuity
Kyle Mikson36%
→ $70ReiteratesBuy → BuyGet Alert
08/07/2023Buy Now596.3%Morgan Stanley
Tejas Savant50%
$65 → $65ReiteratesOverweight → OverweightGet Alert
08/04/2023Buy Now607.02%Barclays
Luke Sergott50%
$65 → $66MaintainsOverweightGet Alert
08/04/2023Buy Now703.43%Citigroup
Patrick Donnelly80%
$65 → $75MaintainsBuyGet Alert
07/13/2023Buy Now221.37%Goldman Sachs
Matthew Sykes62%
$25 → $30MaintainsSellGet Alert
05/18/2023Buy Now596.3%Stephens & Co.
Mason Carrico39%
→ $65ReiteratesOverweight → OverweightGet Alert
05/10/2023Buy Now596.3%Barclays
Luke Sergott50%
→ $65Initiates → OverweightGet Alert
05/04/2023Buy Now628.44%Stifel
Daniel Arias78%
$57 → $68MaintainsBuyGet Alert
05/04/2023Buy Now607.02%TD Cowen
Dan Brennan62%
$62 → $66MaintainsOutperformGet Alert
05/04/2023Buy Now596.3%Canaccord Genuity
Kyle Mikson36%
$58 → $65MaintainsBuyGet Alert
05/04/2023Buy Now596.3%Stephens & Co.
Mason Carrico39%
→ $65Reiterates → OverweightGet Alert
03/31/2023Buy Now596.3%Stephens & Co.
Mason Carrico39%
→ $65Initiates → OverweightGet Alert
02/16/2023Buy Now596.3%Morgan Stanley
Tejas Savant50%
$64 → $65MaintainsOverweightGet Alert
02/16/2023Buy Now521.32%Canaccord Genuity
Kyle Mikson36%
$55 → $58MaintainsBuyGet Alert
02/16/2023Buy Now510.61%Cowen & Co.
Dan Brennan62%
$52 → $57MaintainsOutperformGet Alert
02/02/2023Buy Now435.62%UBS
John Sourbeer32%
→ $50Initiates → NeutralGet Alert
12/14/2022Buy Now435.62%Deutsche Bank
Justin Bowers46%
→ $50Initiates → BuyGet Alert
11/04/2022Buy Now585.59%Morgan Stanley
Tejas Savant50%
$70 → $64MaintainsOverweightGet Alert
10/13/2022Buy Now167.81%Goldman Sachs
Matthew Sykes62%
$35 → $25MaintainsSellGet Alert
08/18/2022Buy Now274.93%Goldman Sachs
Matthew Sykes62%
$55 → $35DowngradeNeutral → SellGet Alert
08/10/2022Buy Now649.87%Morgan Stanley
Tejas Savant50%
$100 → $70MaintainsOverweightGet Alert
07/15/2022Buy Now435.62%Cowen & Co.
Dan Brennan62%
$90 → $50MaintainsOutperformGet Alert
07/15/2022Buy Now274.93%B of A Securities
Derik De Bruin84%
$80 → $35DowngradeNeutral → UnderperformGet Alert
07/15/2022Buy NowWilliam Blair
Brian Weinstein28%
DowngradeOutperform → Market PerformGet Alert
07/14/2022Buy Now542.74%Goldman Sachs
Amit Hazan56%
$80 → $60MaintainsNeutralGet Alert

FAQ

Q

What is the target price for 10x Genomics (TXG) stock?

A

The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Morgan Stanley on May 19, 2025. The analyst firm set a price target for $18.00 expecting TXG to rise to within 12 months (a possible 92.82% upside). 42 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for 10x Genomics (TXG)?

A

The latest analyst rating for 10x Genomics (NASDAQ:TXG) was provided by Morgan Stanley, and 10x Genomics maintained their overweight rating.

Q

When was the last upgrade for 10x Genomics (TXG)?

A

The last upgrade for 10x Genomics Inc happened on July 22, 2024 when Jefferies raised their price target to $24. Jefferies previously had a hold for 10x Genomics Inc.

Q

When was the last downgrade for 10x Genomics (TXG)?

A

The last downgrade for 10x Genomics Inc happened on February 13, 2025 when Leerink Partners changed their price target from $25 to $12 for 10x Genomics Inc.

Q

When is the next analyst rating going to be posted or updated for 10x Genomics (TXG)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 10x Genomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 10x Genomics was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.

Q

Is the Analyst Rating 10x Genomics (TXG) correct?

A

While ratings are subjective and will change, the latest 10x Genomics (TXG) rating was a maintained with a price target of $26.00 to $18.00. The current price 10x Genomics (TXG) is trading at is $9.34, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch